AKTX (Akari Therapeutics) Buyback Yield %: -48.55 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTX Akari Therapeutics PLC AKTX
30 GF Score
Price $11.01
View Full Analysis

What is Akari Therapeutics Buyback Yield %?

Akari Therapeutics AKTX -4.26% 30 Buyback Yield % is -48.55 as of Jul. 19, 2026. GuruFocus rates AKTX with a GF Score™ of 30/100. Among 740 Biotechnology companies, Akari Therapeutics ranks worse than 82.57% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Akari Therapeutics's current buyback yield was -48.55%.

Akari Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics Buyback Yield % Chart

Akari Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.19 -72.06 -34.07 -36.41 -81.96

Akari Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.52 -23.27 -27.36 -81.96 -158.66

AKTX vs MBRX, JAGX, ANEB: Buyback Yield % Comparison

For the Biotechnology subindustry, Akari Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Buyback Yield % falls into.


AKTX
30GF Score
Akari Therapeutics PLC AKTX
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Akari Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10.725) / 13.08592
=-81.96%

Akari Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 9.356) / 5.89675
=-158.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -48.55 mean?
Akari Therapeutics (AKTX) has a Buyback Yield % of -48.55 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #611 out of 740 companies in the Biotechnology industry, placing it in the top 82.6%.
Is Akari Therapeutics' Buyback Yield % too high?
Akari Therapeutics' current Buyback Yield % is -48.55. Based on the distribution chart, Akari Therapeutics ranks #611 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Akari Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Buyback Yield % compare to MBRX and JAGX?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #611 out of 740 companies for Buyback Yield %. This places Akari Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Buyback Yield % is -48.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current Buyback Yield % of -48.55. The current Buyback Yield % is -48.55. Akari Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Buyback Yield % is -48.55 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
30GF Score

Get the complete analysis for AKTX

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.01
Price